Barclays
LYEL icon

Barclays’s Lyell Immunopharma LYEL Stock Holding History

Barclays’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.5K Sell
1,671
-14,296
-90% -$334K ﹤0.01% 4445
2025
Q4 		$491K Buy
15,967
+14,775
+1,240% +$331K ﹤0.01% 3854
2025
Q3 		$19.4K Buy
1,192
+37
+3% +$423 ﹤0.01% 4938
2025
Q2 		$10.2K Sell
1,155
-8,018
-87% -$73.1K ﹤0.01% 4913
2025
Q1 		$98.7K Sell
9,173
-3,746
-29% -$45.9K ﹤0.01% 4415
2024
Q4 		$165K Buy
12,919
+888
+7% +$17.6K ﹤0.01% 4391
2024
Q3 		$332K Buy
12,031
+9,116
+313% +$268K ﹤0.01% 4025
2024
Q2 		$84.5K Sell
2,915
-4,412
-60% -$210K ﹤0.01% 3985
2024
Q1 		$327K Sell
7,327
-5,827
-44% -$250K ﹤0.01% 3845
2023
Q4 		$510K Buy
13,154
+892
+7% +$32.1K ﹤0.01% 3859
2023
Q3 		$361K Buy
12,262
+2,349
+24% +$112K ﹤0.01% 2986
2023
Q2 		$630K Sell
9,913
-2,350
-19% -$130K ﹤0.01% 2605
2023
Q1 		$579K Sell
12,263
-4,507
-27% -$241K ﹤0.01% 3163
2022
Q4 		$1.16M Buy
16,770
+10,035
+149% +$997K ﹤0.01% 2681
2022
Q3 		$988K Buy
6,735
+6,301
+1,452% +$853K ﹤0.01% 2244
2022
Q2 		$57K Sell
434
-1,198
-73% -$122K ﹤0.01% 3988
2022
Q1 		$164K Buy
+1,632
New +$198K ﹤0.01% 3541

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's LYEL Position: Q1 2026 in Review

Barclays reduced its Lyell Immunopharma (LYEL) stake by 90% in Q1 2026, selling an estimated $334K and leaving 1,671 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4445.

Barclays first reported a position in LYEL in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.16M in Q4 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Barclays held 1,671 shares of Lyell Immunopharma worth $33.5K as of Q1 2026.
  • Barclays sold 14,296 Lyell Immunopharma shares in Q1 2026, an estimated $334K.
  • Lyell Immunopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4445 holding.
  • Barclays first reported a position in Lyell Immunopharma in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Lyell Immunopharma position peaked at $1.16M in Q4 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.